NCT02412761View on ClinicalTrials.gov

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Essential Hypertension
Interventions
DRUG

Lisinopril

Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.

DRUG

Amlodipine

Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose

DRUG

Hydrochlorothiazide

Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose

Trial Locations (1)

77030

University of Texas at Houston Medical School; Pediatric Nephrology and Hypertension Clinics, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT02412761 - Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension | Biotech Hunter | Biotech Hunter